Cases & Deals

PTC Therapeutics develops global patent portfolio for small molecule therapeutics

Clients PTC THERAPEUTICS, INC.

Jones Day represents PTC Therapeutics, Inc. in the establishment of a global patent portfolio related to nonsense mutation suppressor TRANSLARNA® for the treatment of Duchenne Muscular Dystrophy ("DMD") and alternative splicing compounds for the treatment of Spinal Muscular Atrophy ("SMA").

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.